Norditropin NordiFlex®

DRUG3 trials

Conditions

Adult Growth Hormone DeficiencyChronic Kidney DiseaseChronic Renal InsufficiencyDelivery SystemsFoetal Growth ProblemGenetic DisorderGrowth Hormone Deficiency in ChildrenGrowth Hormone Disorder

Phase 1

A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

CompletedNCT01706783

Novo Nordisk A/SAdult Growth Hormone Deficiency, Growth Hormone Disorder

Start: 2012-10-12End: 2013-11-18Updated: 2020-12-24

Phase 4

Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents

CompletedNCT01245374

Novo Nordisk A/SChronic Kidney Disease, Chronic Renal Insufficiency, Delivery Systems +6

Start: 2010-11-30End: 2011-04-30Updated: 2017-02-27

Unknown Phase

Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone

CompletedNCT01327924

Novo Nordisk A/SChronic Kidney Disease, Chronic Renal Insufficiency, Delivery Systems +6

Start: 2011-04-30End: 2012-06-30Updated: 2014-06-24

Related Papers

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin<sup>®</sup> in Children and Adults.

2021-04-176 citations

Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials